Corporate Presentation 1 January 2021 S E E K I N G G E N E T H E R A P Y C U R E S NASDAQ: RCKT Cautionary Statement Regarding Forward-Looking Statements 2 Important Information Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding its guidance for 2020 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesi ...

pharma 1 ASH: Breakout Session December 8, 2019 Q&A Panelists Brian Beard, Ph.D.: AVP, Chemistry Manufacturing and Control, LVV & AAV, Rocket Pharmaceuticals Agnieszka Czechowicz M.D., Ph.D.: Assistant Professor of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine at the Stanford University School of Medicine (FA) Donald (Don) Kohn, M.D.: Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics Molecular and Medical Pharmacology Professor at UCLA and Principal Inves ...

·p·h a r m a August 2019 Important Information Cautionary Statement Regarding Forward-Looking Statements Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding the safety, effectiveness and timing of product candidates that Rocket may develop, including in collaboration with academic partners, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantil ...